Eli Lilly has entered into an agreement with Insilico Medicine, a company that develops drugs using artificial intelligence. The deal includes an initial payment of $115 million to Insilico. The total value of the deal can reach up to $2.75 billion, including future payments dependent on the success of drug development (so-called biobucks). The focus of cooperation and specific therapeutic areas were not specified in the article.